1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Methylprednisolone Tablets
Trade Name: MEDROL
Chemical Family: Corticosteroid hormone
Intended Use: Pharmaceutical active used as anti-inflammatory

2. HAZARDS IDENTIFICATION

Appearance: Tablets, varying in color depending on strength
Signal Word: DANGER

Statement of Hazard:
May damage the unborn child.
May cause damage to blood and blood forming organs through prolonged or repeated exposure.

Short Term: May be absorbed through the skin and cause systemic effects.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs. May cause allergic reactions in susceptible individuals following repeated contact with this material.

Known Clinical Effects: Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations.
EU Indication of danger: Toxic to reproduction: Category 1
Harmful

EU Hazard Symbols:

EU Risk Phrases:
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.
R61 - May cause harm to the unborn child.

Australian Hazard Classification (NOHSC):
2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone</td>
<td>83-43-2</td>
<td>201-476-4</td>
<td>T;R48/22</td>
<td>2, 4, 8, 16 or 32mg***</td>
</tr>
<tr>
<td>Calcium stearate</td>
<td>1592-23-0</td>
<td>216-472-8</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>8012-95-1</td>
<td>232-384-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorbic acid</td>
<td>110-44-1</td>
<td>203-768-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May include oxides of carbon.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable
6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections:
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions:
Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Methylprednisolone
Pfizer OEL TWA-8 Hr:
4 µg/m³, Skin µg/m³,

Calcium stearate
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Corn Starch
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Czech Republic OEL - TWA 4.0 mg/m³
Greece OEL - TWA 5 mg/m³
Ireland OEL - TWAs 4 mg/m³
OSHA - Final PELS - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Slovakia OEL - TWA 4 mg/m³
Spain OEL - TWA 10 mg/m³

METHYPREDNISOLONE TABLETS
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Mineral oil

<table>
<thead>
<tr>
<th>Source</th>
<th>Threshold Limit Value (TWA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Australia OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>5.0 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Denmark OEL - TWA</td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Finland OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Netherlands OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs:</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>1 mg/m³</td>
</tr>
<tr>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Sweden OEL - TWAs</td>
<td>1 mg/m³</td>
</tr>
</tbody>
</table>

Sucrose

<table>
<thead>
<tr>
<th>Source</th>
<th>Threshold Limit Value (TWA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Australia OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>10.0 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs:</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>6 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
</tbody>
</table>


Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets
Molecular Formula: Mixture
Color: Various
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose
Rat Oral LD50 > 29.7 g/kg

Lactose
Rat Oral LD50 > 10 g/kg

Sorbic acid
Rat Oral LD50 7360 mg/kg
Mouse Oral LD50 3200 mg/kg

Methylprednisolone
Rat Oral LD 50 > 2000 mg/kg
Mouse Oral LD 50 450 mg/kg
Rat Intraperitoneal LD 50 1000 mg/kg
Mouse Intraperitoneal LD 50 1409 mg/kg
Rat Subcutaneous LD 50 >3000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Mineral oil
Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Methylprednisolone
Skin Irritation Rabbit No effect
Eye Irritation Rabbit No effect
Skin Sensitization - GPMT Guinea Pig No effect
11. TOXICOLOGICAL INFORMATION

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Methylprednisolone
42 Day(s) Dog Oral 167 µg/kg/day LOAEL Adrenal gland
6 Week(s) Rat Subcutaneous 500 µg/kg/day LOAEL None identified
14 Week(s) Rat Subcutaneous 0.4 µg/kg/day NOAEL Blood forming organs, Adrenal gland
52 Week(s) Rat Subcutaneous 4 µg/kg/day NOAEL Blood forming organs Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Methylprednisolone
Reproductive & Fertility Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity
Reproductive & Fertility Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic
Embryo / Fetal Development Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic
Embryo / Fetal Development Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose
Bacterial Mutagenicity (Ames) Salmonella Negative

Methylprednisolone
Bacterial Mutagenicity (Ames) Salmonella Negative
Unscheduled DNA Synthesis Rat Hepatocyte Negative
Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
Direct DNA Interaction Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic to reproduction: Category 1
Harmful

EU Risk Phrases:
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.
R61 - May cause harm to the unborn child.

EU Safety Phrases:
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
DANGER
May damage the unborn child.
May cause damage to blood and blood forming organs through prolonged or repeated exposure.

Canada - WHMIS: Classifications
WHMIS hazard class:
D2a very toxic materials

Methylprednisolone
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List 201-476-4

Calcium stearate
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 216-472-8

Corn Starch
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the obligations of Register:  Present
EU EINECS/ELINCS List  232-679-6

Sorbian acid
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
EU EINECS/ELINCS List  203-768-7

Lactose
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
REACH - Annex IV - Exemptions from the obligations of Register:  Present
EU EINECS/ELINCS List  200-559-2

Mineral oil
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
EU EINECS/ELINCS List  232-384-2

Sucrose
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
REACH - Annex IV - Exemptions from the obligations of Register:  Present
EU EINECS/ELINCS List  200-334-9

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3
R61 - May cause harm to the unborn child.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources:  Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:  Updated Section 7 - Handling and Storage. Updated Section 15 - Regulatory Information.
Prepared by:  Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet